Nurix Therapeutics, Inc. (NASDAQ: NRIX) is a Healthcare company (Biotechnology) with a market capitalization of $1.6B. The Maz Rating grades it against the other companies in its sector.
Nurix Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $14.23, Nurix Therapeutics, Inc. trades at 5.7x trailing earnings, 2.2x sales and 1.6x book value, with an EV/EBITDA of 2.8. Over the last twelve months it generated about $702M of revenue and $274M of net income. It runs a gross margin of 86.5%, an operating margin of 41.3% and a net margin of 42.0%. It shows return on equity of 49.3%, return on invested capital of 26.0% and a free cash flow yield of 23.8%. On the balance sheet: a debt-to-equity ratio of 0.07 and a current ratio of 8.44. Over the past 52 weeks the share price ranged from $12.43 to $28.23, with a beta of 1.80.
Nurix Therapeutics, Inc. does not currently pay a dividend.
19 Wall Street analyst ratings cover the stock: 18 Buy and 1 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton’s tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of August 2026, Nurix Therapeutics, Inc. (NRIX) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 40.3% / 30% · Interest income / Revenue 0.59% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 39.8% / 33% · Receivables / Mkt Cap (36m) 0.76% / 49% · Interest income / Revenue 0.59% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 39.8% / 33.33% · Receivables / Mkt Cap (24m) 0.76% / 33.33% · Interest income / Revenue 0.59% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.00% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 85.9% / 33.33% · Receivables / Avg Assets (4Q) 0.73% / 33.33% · Interest income / Revenue 0.59% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 87.7% / 33.33% · (Cash+Recv) / Total Assets 89.4% / 33.33% · Interest income / Revenue 0.59% / 5% | Fail |
No. As of August 2026, Nurix Therapeutics, Inc. (NRIX) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Nurix Therapeutics, Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m).
About 0.59% of each dividend: Nurix Therapeutics, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated August 31, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.